News

A 5-year-old boy with an inflammatory skin condition developed Cushing’s syndrome following a year of his parents’ use of a topical corticosteroid cream to treat his psoriasis, according to a new case study. The researchers noted that this case “underlines the potential side effects of high-potency corticosteroids.” Although the…

People with Cushing’s syndrome are at an increased risk of experiencing dangerous blood clotting events in the years following diagnosis, according to a recent study. These data underscore “the critical need for heightened vigilance and targeted management strategies in this high-risk population,” researchers wrote. The study, “Can…

Partial adrenalectomy, or the removal of only a portion of the adrenal gland containing a tumor instead of the entire gland, using a minimally invasive procedure is safe and feasible in people with Cushing’s syndrome and other conditions, according to a study in Germany. The procedure, called posterior retroperitoneoscopic partial…

Older Cushing’s disease patients less frequently present classical symptoms of the disease, and have more coexistent conditions and larger tumors than those who develop the disease at a younger age. That’s according to a study that analyzed patients at several sites in the U.S. who underwent surgery to…

A rare and aggressive form of thyroid cancer caused Cushing’s syndrome in a man in his 30s, according to a case report. “This case underscores the complexity of diagnosing and managing ectopic Cushing’s syndrome, particularly when it is secondary to a rare malignancy,” researchers wrote. The case report, “…

Corcept Therapeutics has asked the U.S. Food and Drug Administration (FDA) to approve relacorilant for people with endogenous Cushing’s syndrome. “Relacorilant’s combination of efficacy and safety give it the potential to become the standard of care for the medical treatment of patients with hypercortisolism,” Joseph Belanoff, MD, CEO…

Long-term treatment with relacorilant led to a sustained decrease in blood pressure, blood sugar levels, and body weight in people with Cushing’s syndrome, new data from an extension study shows. The extension study (NCT03604198) is assessing relacorilant’s long-term safety and efficacy in 116 people with Cushing’s who completed…

Korlym (mifepristone) significantly reduced levels of hemoglobin A1c, a marker that reflects blood sugar levels over the previous months, in people with Cushing’s syndrome and difficult-to-control type 2 diabetes. That’s according to new data from a Phase 4 clinical trial, CATALYST (NCT05772169), which screened 1,057 patients with difficult-to-control…

An elderly woman developed Cushing’s syndrome after a year of using a so-called magic mouthwash — a rinse containing a potent topical corticosteroid — to treat an inflammatory disease affecting the mouth, according to a case study from Australia. About two months after stopping use of the steroid mouthwash,…

Patients being treated with Isturisa (osilodrostat) for Cushing’s disease see better long-term clinical outcomes when both late-night salivary cortisol and mean urinary free cortisol returned to normal levels, instead of just one or neither of those measures. Drawing on data from two Phase 3 clinical studies, LINC-3…